Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

185 results about "Crohn disease" patented technology

Crohn's Disease Crohn's disease is a chronic inflammatory disease of the digestive tract. ... Crohn’s disease causes inflammation in part of your digestive system. Crohn's can affect any part of it, but most often it affects your small intestine and colon.

Materials and methods for treatment of gastrointestinal disorders

The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and / or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.
Owner:THERAPEUTIC RES

Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen

The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence of IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
Owner:RGT UNIV OF CALIFORNIA +1

Genemap of the human genes associated with crohn's disease

InactiveUS20090081658A1Reduce frequencyTreatment safetyMicrobiological testing/measurementGenomicsLinkage Disequilibrium Mapping
The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Methods of treating crohn's disease and ulcerative colitis

The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and / or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and / or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
Owner:ABBVIE INC

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2 / CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2 / CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.
Owner:CEDARS SINAI MEDICAL CENT

Genemap of the human genes associated with crohn's disease

The present invention relates to the selection of a set of polymorphism makers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (ex: Chrohn's disease) and / or their response to a particular drug or drugs.
Owner:BELOUCHI ABDELMAJID +12

Methods of diagnosing inflammatory bowel disease

The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and / or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and / or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.
Owner:PROMETHEUS LAB

Genemap of the human genes associated with crohn's disease

InactiveUS20100081129A1Genetic material ingredientsMicrobiological testing/measurementLinkage Disequilibrium MappingPharmacogenomic Study
The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Method of selecting therapeutic indications

Methods of treatment for Crohn's disease and multiple sclerosis are disclosed. Also disclosed are methods for repositioning a pharmaceutical by selecting at least one target gene, gene product, or loci associated with the treatment of at least one first disease, trait, or phenotype by the pharmaceutical, identifying at least one second disease, trait, or phenotype associated with the least one target gene, gene product, or loci using genome-wide associated studies, and selecting at least one identified second disease, trait and / or phenotype based on step for treatment with the pharmaceutical.
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

Methods of predicting the need for surgery in crohn's disease

ActiveUS20120208900A1Fast progressDiagnosing susceptibilityBiocideAntipyreticGenetic riskCvd risk
The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
Owner:CEDARS SINAI MEDICAL CENT

Serological markers of inflammatory bowel disease phenotype and disease progression

Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease.
Owner:DENSON LEE A +2

Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease

The present invention is related to a hyaluronic acid formulation including a mixture of hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Crohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.
Owner:HOLY STONE HEALTHCARE CO LTD

O-glycans as diagnostic markers for inflammatory bowel disease

The present invention provides diagnostic methods for inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising assessing expression, structure and / or function of O-glycans in a sample from a subject, as well as antibodies to such molecules.
Owner:OKLAHOMA MEDICAL RES FOUND

Application of bacillus coagulans in preparing medicine for treating inflammatory bowel disease

The invention discloses new medical application of bacillus coagulans, particularly relates to application of the bacillus coagulans in preparing a medicine for treating an inflammatory bowel disease. The inflammatory bowel disease refers to ulcerative colitis and a crohn disease; the bacillus coagulans is selected but not limited from the bacillus coagulans preserved in the The China General Microbiological Culture Collection Center (CGMCC) with the preservation number of 1207. The bacillus coagulans has outstanding treatment effect when being used for treating the crohn disease as a medical active component and belongs to the field of biological medicines.
Owner:QINGDAO EASTSEA PHARMA +1

Application of artemisinin derivative in preparation of medicaments for treating Crohn disease

InactiveCN102048728AFew and mild side effectsAchieving the goal of treating Crohn's diseaseOrganic active ingredientsDigestive systemSide effectHepatic dysfunction
The invention discloses an application of an artemisinin derivative in preparation of medicament for treating Crohn disease, and the artemisinin derivative is selected from artesunate or artemether or styrene monomer 905 (SM905). The artemisinin derivative can be used for achieving the purpose of treating the Crohn disease by inhibiting Th1 / Th17 immune response and inhibiting nuclear factor-kB activation. Compared with the existing medicaments, the artemisinin derivative has less and light side effects, in one year of following visits for the treatment of rheumatoid arthritis, transient reticulocyte decline and hepatic dysfunction only occur in individual cases, and the health can be restored by liver protection treatment without medicament withdrawal. Therefore, the artemisinin derivative can be taken by patients for a long time, the treatment can be maintained, and the purpose of effective treatment can be achieved.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Enhanced t cell receptor-mediated tumor necrosis factor superfamily and chemokine mRNA expression in peripheral blood leukocytes in patients with crohn's disease

A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.
Owner:CEDARS SINAI MEDICAL CENT

Application of clostridium butyricum and condensate bacillus in the preparation of medicament for treating inflammatory bowel disease

The present invention discloses a new medicine purpose of Clostridium butyricum and Bacillus coagulans, in particular relates to an application of Clostridium butyricum and Bacillus coagulans in preparing the medicine for curing inflammatory bowel diseases. The inflammatory bowel disease refers to an ulcerative colitis and a Crohn disease. The Clostridium butyricum is selected from but not limited to Clostridium butyricum, CGMCC and the preservation number is 0313.1; the Bacillus coagulans is selected from but not limited to Bacillus coagulans, CGMCC and the preservation number is 1270. The Clostridium butyricum and Bacillus coagulans as a single pharmaceutical active ingredient or a combined pharmaceutical active ingredient has significant curative effect on ulcerative colitis and Crohn's disease, pertaining to the art of biological medicine.
Owner:QINGDAO EASTSEA PHARMA +1

Methods for treating inflammation, autoimmune disorders and pain

Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and / or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
Owner:BRIGHAM YOUNG UNIV

Enteroscopy Crohn's disease auxiliary diagnosis system and method based on deep learning

The invention discloses an enteroscopy Crohn's disease auxiliary diagnosis system and method based on deep learning. The system comprises an enteroscopy image automatic acquisition subsystem, a database, a client and a server. The enteroscope image automatic acquisition subsystem is used for acquiring an enteroscope image; wherein the database comprises a sample set for training the convolutionalneural network; and the client is used for uploading the enteroscopy image acquired by the enteroscopy image automatic acquisition subsystem to the server, and receiving and displaying an analysis result fed back by the server. According to the method, an image recognition technology is utilized to monitor an endoscope video in real time, images containing key organ parts and suspicious Crohn focus areas are automatically collected, and after global preferences are made according to a weighting algorithm, whether the image is Crohn disease or not is diagnosed. According to the method, after the neural network model is utilized to automatically screen the images, the most valuable image can be extracted from the global video, auxiliary diagnosis is given, and more reliable and efficient support is provided for doctors to diagnose.
Owner:武汉大学人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products